SOURCE: OmniComm Systems, Inc.

April 21, 2008 09:30 ET

OmniComm Systems, Inc.'s Success in Delivering Top Quality Electronic Data Capture (EDC) Solutions & Services Continues With Yet Another Strong Quarter

Over $3 Million in Contracts Are Booked in Q1, Representing an Increase in Bookings of 40% From Q1 Last Year

FT. LAUDERDALE, FL--(Marketwire - April 21, 2008) - OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that customer momentum is building as the company continues to experience dynamic growth. OmniComm attributes its success to providing quality EDC solutions and services and partnering with innovative companies that deliver the clinical trial support services that today's drug development companies demand.

In the first quarter of 2008, OmniComm added five new clients to its customer list, added four more trials from repeat customers, and added six new partners to its very successful Preferred Partnership Programs. Three contract research organizations (CROs) joined the CRO Preferred Program™ (Clintech Research LLC, Criterium Inc. and Pleiad Inc.) and three new companies became alliance partners (Clinical Ink, IVR Clinical Concepts and Logos Technologies). The unique mix of quality deliverables, dependability and innovative solutions that these partnerships bring continues to help drive business for OmniComm.

"Historically the first quarter has been relatively slow, so we are extremely encouraged by our very strong start in the first quarter of 2008," said Stephen Johnson, COO of OmniComm. "Our company is experiencing banner growth as a result of our quality solutions and world-class customer service. We have a superior EDC product and offer a complete solution through partnerships and integration with complimentary companies and we have a solid workforce of clinical professionals on board. Some of our recent hires at OmniComm include Sondra Smyrnios, our Sr. VP of Clinical Operations and Dale Clark, our Director of Quality Management Systems. Sondra brings over 14 years of pharmaceutical experience to OmniComm with previous positions at Kos Pharmaceuticals, Sanofi-Synthelabo Canada, Eli Lilly and Janssen-Ortho. Dale comes to us with over 25 years of quality management experience having held positions with Liberty Medical (Medco), Franklin Templeton, GoSolutions, Arthur Anderson, Arbor Health Care, Medical Systems and DataChem. We believe that the right combination of people and performance is the impetus for our success and our clients' satisfaction."

Q1 New Contracts 2008:

Pharmaceutical
   -- 2 month, Phase I, Anxiety study with 1 site and 12 subjects

Biotechnology
   -- 44 month, Phase III, HIV study with 125 sites and 700+ subjects
   -- 44 month, Phase III, HIV study with 125 sites and 700+ subjects
   -- 12 month, Phase III, cardiovascular study with 40 sites and 1000
      subjects
   -- 30 month, Phase III, oncology study with 55 sites and 300 subjects

Medical Device
   -- 60 month, Pivotal, cardiovascular study with 50 sites and 664
      subjects
   -- 9 month, ophthalmology study with 8 sites and 32 subjects

Academic
   -- 18 month, Phase III, cardiovascular-infectious disease study with 10
      sites and 60 subjects
   -- 24 month, Phase I, muscular dystrophy study with 1 site and 6
      subjects

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Contact Information

  • CONTACT:
    Lizanne Kelley
    OmniComm Systems, Inc.
    954-473-1254 Extension 283
    Email Contact